Completion of acquisition, Admission & TVR Update

 

Capitalised terms in this announcement carry the same meaning as in the RNS of 28 September 2021, unless otherwise stated

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care business, announces that, further to the announcement on 28 September, the Acquisition of ADL Health has completed.

 

Admission of the Consideration Shares to trading on AIM and Total Voting Rights

The Consideration Shares will, when issued, be credited as fully paid new ordinary shares and will rank equally in all respects with the existing ordinary shares, including the right to receive any dividend or other distribution declared, made or paid after Admission.

For the purposes of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules ("DTRs"), the issued ordinary share capital of the Company following Admission will consist of 463,930,564 ordinary shares each carrying one voting right. There are no ordinary shares held in treasury. From the date of Admission, the figure of 463,930,564 may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, the Company under the DTRs.

 

For further information please contact:

 

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Christopher Mills, Non-executive Chairman

Tel: +44 (0)29 2071 0570

Mike Salter, CEO

 

Richard Evans, FD & COO

 

 

 

Singer Capital Markets (Nominated Adviser & Joint Broker)

Tel: +44 (0)20 7496 3000

Aubrey Powell / George Tzimas / Tom Salvesen

 

 

 

Investec Bank plc (Joint Broker)

Tel: +44 (0)20 7597 4000

Gary Clarence / Daniel Adams

 

 

 

Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or  

Paul McManus / Lianne Cawthorne

Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303 

Back to ListingNext